Physician profile
Scott Mercer
NPI 1295736031
$3,083.99
in general payments reported to CMS, 2019-2025
33 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $317 · 2021: $579 · 2022: $422 · 2023: $540 · 2024: $379 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $606.06 | 2019-2025 | |
| Abbvie INC. | $384.16 | 2021-2023 | |
| Amgen INC. | $259.81 | 2022-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $228.42 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $204.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Eisai INC. | $181.52 | 2021-2022 | |
| Allergan, INC. | $160.32 | 2019-2020 | |
| Novo Nordisk INC | $150.60 | 2021-2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $94.43 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $72.60 | 2019 | |
| Antares Pharma, INC. | $70.02 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Verity Pharmaceuticals INC. | $69.70 | 2024-2025 | Tlando |
| Zyla Life Sciences, INC. | $66.95 | 2019 | |
| Seqirus USA INC | $60.70 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $56.80 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $51.83 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.18 | 2022-2023 | Livalo |
| Itamar Medical INC | $33.96 | 2022-2025 | Watchpatone |
| Linus Health, INC. | $30.50 | 2022 | |
| Lilly USA, LLC | $23.23 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $21.74 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.88 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.36 | 2019 | |
| Astellas Pharma US INC | $19.15 | 2019 | |
| Exact Sciences Corporation | $18.70 | 2023 | Cologuard Collection Kit |
| Halozyme INC | $18.60 | 2023 | |
| Grifols USA, LLC | $18.48 | 2024 | Prolastin-C Liquid |
| Ironshore Pharmaceuticals INC. | $18.00 | 2019 | |
| Lucid Diagnostics INC. | $17.47 | 2025 | |
| Iroko Pharmaceuticals, LLC | $17.35 | 2019 | |
| Adlon Therapeutics L.P. | $15.20 | 2021 | |
| Tolmar, INC. | $14.27 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mercer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.